Keyword: Promethera Biosciences
The agreement tasks Prometheus with identifying and validating three IBD drug targets in return for up to $420 million in milestones.
The series D round comes as Promethera prepares to start testing its lead drug in end-stage NASH patients.
DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.
The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.
Promethera Biosciences has added to its Series C to support its expansion into major liver diseases including nonalcoholic steatohepatitis.
Promethera Biosciences is planning to IPO in April or May to raise €40 million for its pipeline of liver cell therapies.